Prognostic significance of CA125 in patients with ovarian cancer and secondary debulking surgery

Anticancer Research

Volumn 17, Issue 4 B, 1997, Pages 2945-2947

  Meier, Werner ^a   Stieber, Petra ^a   Hasholzner, Ute ^a   Gropp, Martina ^a   Fateh Moghadam, Ahmad ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

CA125; Ovarian cancer; Secondary debulking surgery; Tumor marker

Indexed keywords

CA 125 ANTIGEN;

BLOOD LEVEL; CANCER SURGERY; CANCER SURVIVAL; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME;

CA-125 ANTIGEN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; OVARIAN NEOPLASMS; PROGNOSIS;

EID: 0030767540     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (6)

1. Rath W, Meden H, Brill A, Kuhn W: Ergebnisse bei der operativen Primartherapie des Ovarialkarzinoms. Arch Gynecol 250: 175, 1991.
2. Pfleiderer A: Tumoren des Eierstocks. In: Gynäkologische Onkologie (Bender HG, ed) Thieme, Stuttgart, 1991.
3. Meier W, Romisch M, Hepp H: Stellenwert der tumorreduktiven Sekundäroperation (Interventionslaparotomie) beim Ovarialkarzinom. Geburtsh u Frauenheilk 53: 860, 1993.
4. van der Burg MEL, Lammers FB, Verweij J: Ovarian cancer: The prognostic value of serum half life of CA125 during induction chemotherapy. Gynecol Oncol 30: 307, 1988.
5. Meier W, Stieber P, Fateh-Moghadam A, Eiermann W, Hepp H: Prognostische Bedeutung der CA125 Halbwertszeit für den weiteren Krankheitsverlauf beim Ovarialkarzinom. Geburtsh u Frauenheilk 52: 30, 1992.
6. Potter ME, Moradi M, To AC, Hatch KD, Shingleton HM: Value of serum CA125 levels: Does the results preclude second-look? Gynecol Oncol 33: 201, 1989.